Back to Atlas
CTransientStandard research/education caution
CMP-0466
Approved
Toremifene
Endocrine / SERM
ER-positive breast cancer endocrine therapy positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- SERM
- Primary mechanism
- Estrogen receptor modulation; tamoxifen analog
- Primary market use
- Oncology / endocrine
Pharmacology
- Molecular weight (Da)
- 405.96 base; 598.1 citrate
- Oral bioavailability
- Oral; well absorbed
- Half-life
- ~5 d
- Route tags
- Route-dependent / verify
- Evidence level
- Approved
- Clinical status
- Approved
- Value-for-money score
- 4 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Similar commercial logic to tamoxifen; not a general enhancement compound